No­var­tis nabs FDA ap­proval for hyped Eylea ri­val

As Re­gen­eron’s Eylea stares down po­ten­tial slow-death-by-gener­ics, No­var­tis has nabbed a wide­ly ex­pect­ed FDA ap­proval for its own wet mac­u­lar de­gen­er­a­tion in­jec­tion, Beovu (brolu­cizum­ab). …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER